Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Subtype as a key to reduce heterogeneity of treatment effects in major depressive disorder

Project description

New treatment approach for major depressive disorder

Major depressive disorder (MDD) is a growing public health problem in Europe that results in a high economic burden. MDD recurrence is common as individual responses to treatments vary considerably. Lack of understanding of the causes of variable treatment outcomes prevents the improvement of a proper treatment regimen. MDD has generally been accepted as a heterogeneous disorder. The ERC-funded SUBTREAT project considers subtype as the key to linking aetiological and treatment effect heterogeneity. It will break down the heterogeneous treatment outcomes of MDD into more narrowly defined subtypes with divergent aetiologies. SUBTREAT will use advanced data science approaches to identify novel subtypes, determine divergent causes and develop a novel prediction algorithm for treatment outcomes.

Objective

Major depressive disorder (MDD) is a leading contributor to disability and suicide. It is the most costly brain disorder in Europe. Although multiple treatments are of proven efficacy, individual responses to treatments vary considerably and MDD recurrence is common. There is considerable motivation to improve treatment regimen for individuals with MDD. However, it has been challenging because of the fundamental lack of understanding about the causes of variable treatment outcomes. MDD is widely accepted as a heterogeneous disorder; yet, most research strategies effectively consider MDD as a single disorder. Progress in understanding the variable treatment response will depend on “patient stratification”, i.e. identifying and accounting for patient heterogeneity when evaluating treatment efficacy.

SUBTREAT proposes a unique direction which considers subtype as the key to link aetiological and treatment effect heterogeneity. Our approach is to break down the heterogeneous treatment outcomes of MDD into more narrowly defined subtypes with divergent aetiologies. Specially, I propose three work packages: 1) dissect treatment heterogeneity across subtypes; a particularly innovative aspect of SUBTREAT is that we will use advanced data science approaches to identify novel subtypes which correlate with differential treatment outcomes; 2) determine divergent causes underlying MDD subtypes; we will comprehensively investigate causes at three levels including genetic and causal epidemiological risk factors, and brain cell types; 3) develop a novel prediction algorithm for treatment outcomes stratified by patient subgroups. SUBTREAT will illuminate the causes of MDD subtypes and the principal patterns of how subtypes contribute to differential long-term treatment outcomes. SUBTREAT findings will promote targeted drug development and treatment optimization for patient subgroups to achieve precision psychiatry.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2021-STG

See all projects funded under this call

Host institution

KAROLINSKA INSTITUTET
Net EU contribution
€ 1 500 000,00
Address
NOBELS VAG 5
171 77 STOCKHOLM
Sweden
Region
Östra Sverige Stockholm Stockholms län
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 1 500 000,00

Beneficiaries (1)